IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) announced inducement equity grants on January 29, 2026 under its 2023 Inducement Plan. The Compensation Committee granted non-qualified stock options to purchase 44,200 shares to a newly hired employee at an exercise price of $32.99 per share.

The options have a 10-year term and vest over four years (25% after one year, then monthly over three years), subject to continued service. The grant was made pursuant to Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – IDYA

-2.42%

-2.42% Session close to close

In the Jan 30 session, IDYA declined 2.42%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a routine inducement equity grant of 44,200 non‑qualified stock options at...

Analysis

This announcement details a routine inducement equity grant of 44,200 non‑qualified stock options at an exercise price of $32.99, vesting over four years with a 10‑year term. It is tied to hiring under Nasdaq Listing Rule 5635(c)(4) and does not change IDEAYA’s clinical, regulatory, or financial profile. Investors may track cumulative equity awards and overall share count alongside upcoming trial and regulatory milestones.

Key Figures

Inducement options granted: 44,200 shares Exercise price: $32.99 per share Option term: 10 years +2 more

5 metrics

Inducement options granted 44,200 shares Non-qualified stock options to a newly hired employee

Exercise price $32.99 per share Equal to Nasdaq closing price on January 29, 2026

Option term 10 years Term of the non-qualified stock options

Initial vesting tranche 25% after 1 year First anniversary of vesting commencement date

Subsequent vesting 75% over 3 years Equal monthly installments after first anniversary

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 05	Conference participation	Positive	+3.2%	J.P. Morgan Healthcare Conference presentation and webcast announcement.
Dec 11	Clinical enrollment	Positive	-0.2%	Completion of full enrollment in pivotal OptimUM‑02 Phase 2/3 trial.
Dec 10	IND submission	Positive	-1.3%	IND submission for IDE574, a potential first‑in‑class KAT6/7 inhibitor.
Dec 04	IND clearance	Positive	+4.7%	FDA IND clearance for IDE034, a bispecific ADC licensed from Biocytogen.
Dec 01	IND clearance	Positive	-3.7%	FDA IND clearance for IDE034 enabling Phase 1 trial in solid tumors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often been clinically or strategically positive, but price reactions have been mixed, with slightly more instances of divergence than alignment.

Recent Company History

Over recent months, IDEAYA released several clinically focused and corporate updates, including FDA IND clearances for IDE034 and an IND submission for IDE574, plus full enrollment of the pivotal OptimUM‑02 trial and participation in the 44th Annual J.P. Morgan Healthcare Conference. Price reactions ranged from -3.68% to +4.69%, indicating that even constructive R&D or conference news has not produced consistently positive moves. Today’s inducement grant fits within this cadence of ongoing corporate activity rather than a major development.

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4), equity awards

3 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase an aggregate of 44,200 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity awards financial

"used exclusively for the grant of equity awards to individuals who were not previously employees"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on January 29, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 44,200 shares of the Company's common stock to a newly hired employee. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award Plan (2023 Inducement Plan) as an inducement material to such individual entering into employment with IDEAYA in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of IDEAYA, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $32.99 per share, which is equal to the closing price of IDEAYA's common stock on The Nasdaq Global Select Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to such employee's continued service to IDEAYA on each vesting date.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer 
investor@ideayabio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302674815.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

What did IDEAYA (IDYA) grant on January 29, 2026 under the 2023 Inducement Plan?

IDEAYA granted non-qualified stock options to purchase 44,200 shares to a newly hired employee. According to IDEAYA, the options carry a $32.99 exercise price, equal to the closing Nasdaq price on the grant date, and were made under Nasdaq rule 5635(c)(4).

What are the exercise price and term of the IDYA inducement stock options?

The options have an exercise price of $32.99 per share and a 10-year term. According to IDEAYA, the exercise price equals the closing price on the grant date and the options expire ten years after grant if unexercised.

How do the IDYA inducement options vest and when is first vesting?

The options vest over four years: 25% vests on the first anniversary, then the remaining 75% vests monthly over three years. According to IDEAYA, vesting is contingent on the employee's continued service on each vesting date.

Why did IDEAYA use the 2023 Inducement Plan for the IDYA grant?

The 2023 Inducement Plan is used to grant equity awards to new hires as an inducement to join the company. According to IDEAYA, the grant was made pursuant to Nasdaq Listing Rule 5635(c)(4) for employees not previously employed by the company.

Will the IDYA inducement grant immediately dilute existing shareholders?

The grant creates the potential for future dilution if options are exercised, but no immediate dilution occurs until exercise. According to IDEAYA, the company granted options for 44,200 shares; actual dilution depends on future exercise and share issuance.